At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Avacincaptad Pegol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Avacincaptad Pegol and Lucentis for Neovascular Age-related Macular Degeneration. Completed, enrolled 64 participants across 28 sites in 3 countries.
Detailed Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHungary, Latvia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedDec 2017
Primary CompletionOct 2018
TodayJul 2026
First PostedDec 5, 2017
Enrollment StartOct 11, 2017
Primary CompletionOct 18, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.6 years ago
Interventions
Avacincaptad Pegoldrug
Avacincaptad Pegol in combination with Lucentis
Lucentisdrug
Avacincaptad Pegol in combination with Lucentis